Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
Article first published online: 28 SEP 2010
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 32, Issue 11-12, pages 1323–1331, December 2010
How to Cite
Chan, H. L.-Y., Wong, V. W.-S., Chim, A. M.-L., Chan, H.-Y., Wong, G. L.-H. and Sung, J. J.-Y. (2010), Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 32: 1323–1331. doi: 10.1111/j.1365-2036.2010.04474.x
- Issue published online: 2 NOV 2010
- Article first published online: 28 SEP 2010
- Publication data Submitted 27 June 2010 First decision 22 July 2010 Resubmitted 30 July 2010 Accepted 8 September 2010 EV Pub Online 28 September 2010
Aliment Pharmacol Ther 2010; 32: 1323–1331
Background On-treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection.
Aim To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response.
Methods Hepatitis B e antigen-positive chronic hepatitis B patients who received peginterferon for 32–48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA <10 000 copies/mL until 12 months post-treatment.
Results Twenty-one of 92 (23%) patients achieved sustained response. At month 6, the area under receiver operating characteristics curve for hepatitis B surface antigen to predict sustained response was 0.77 (95% confidence interval 0.65–0.89, P < 0.001). An hepatitis B surface antigen cutoff at 300 IU/mL at month 6 could give the maximum combination of sensitivity (62%) and specificity (89%) to predict sustained response. Nine of 21 (43%) sustained responders vs. 9 of 71 (13%) nonsustained responders had >1 log hepatitis B surface antigen reduction at month 6 (P < 0.001). Combined hepatitis B surface antigen ≤300 IU/mL and >1 log reduction at month 6 had sensitivity, specificity, positive and negative predictive values of 43%, 96%, 75% and 85% to predict sustained response, respectively.
Conclusion On-treatment serum hepatitis B surface antigen can predict response to peginterferon therapy in chronic hepatitis B.